BriaCell Therapeutics (TSE:BCT) Trading Down 4.2% – Time to Sell?

BriaCell Therapeutics Corp. (TSE:BCT) was down 4.2% on Friday . The company traded as low as C$5.10 and last traded at C$5.21. Approximately 37,392 shares were traded during trading, an increase of 2% from the average daily volume of 36,693 shares. The stock had previously closed at C$5.44.

BriaCell Therapeutics Stock Performance

The stock has a market capitalization of C$37.77 million, a price-to-earnings ratio of -0.15 and a beta of 2.15. The business has a 50-day moving average of C$7.49 and a 200-day moving average of C$11.62.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.